<DOC>
	<DOCNO>NCT00956761</DOCNO>
	<brief_summary>This trial annual registration update seasonal influenza vaccine formulation .</brief_summary>
	<brief_title>Safety Immunogenicity Surface Antigen , Inactivated , Adjuvanted With MF59C.1 , Seasonal Influenza Vaccine , Formulation 2009-2010</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>MF59 oil emulsion</mesh_term>
	<criteria>Key Subjects 65 year age old Mentally competent Willing able give write informed consent prior study entry Able comply study requirement In general good health Key Any serious chronic acute disease disease History anaphylactic reaction and/or serious allergic reaction follow vaccination A proven hypersensitivity component study vaccine Known suspect ( high risk develop ) impairment/alteration immune function ( exclude normally associate advanced age ) Bleeding diathesis condition associate prolonged bleeding time investigator 's opinion would interfere safety subject Within past 12 month , participant receive one injection influenza vaccine Within past 6 month , participant laboratory confirm influenza disease receive influenza vaccine</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Influenza vaccine</keyword>
</DOC>